ScreenerHero

PSNL Personalis, Inc.

NAS · US · Healthcare · Diagnostics & Research · personalis.com
16.00USD-0.19%Mkt Cap: 1.71B $P/E: —

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of mi…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap1.71B USD
Enterprise Value1.54B USD
Revenue (TTM)69.67M USD
Gross Profit15.78M USD
Net Income (TTM)-81.27M USD
Revenue/Share0.71 USD
Last Price16.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees259
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.05
PEG—
EV/EBITDA-14.70
EV/Revenue22.07
P/S24.56
P/B7.25
EPS (TTM)-1.06
EPS (Forward)-0.94
52W Range
4.95579% of range18.89
52W High18.89 USD
52W Low4.955 USD
Profitability
Gross Margin22.65%
Oper. Margin-150.25%
EBITDA Margin-150.13%
Profit Margin-116.69%
ROE-31.12%
ROA-24.32%
Growth
Revenue Growth30.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.95M USD
CapEx (TTM)4.50M USD
FCF Margin-80.42%
FCF Yield-3.28%
Net Debt-174.66M USD
Net Debt/EBITDA1.67
Balance Sheet
Debt/Equity0.15
Current Ratio5.28
Quick Ratio4.91
Book Value/Sh2.21 USD
Cash/Share1.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)15.44 USD
Upside (mean)-3.5%
Target Range13.00 USD – 16.25 USD
13.00-3.5% to mean16.25
# Analysts4
Ownership
Shares Out.106.75M
Float86.37M
Insiders26.15%
Institutions66.82%
Short Interest
Short Ratio2.3d
Short % Float12.09%
Short % Out.7.74%
Shares Short8.27M
Short (prev mo.)8.40M
Technical
SMA 5015.49 (+3.3%)
SMA 20010.57 (+51.4%)
Beta2.32
S&P 52W Chg16.45%
Avg Vol (30d)2.60M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)50.0
MACD0.2122
MACD Signal0.3588
MACD Hist.-0.1466
BB Upper16.86 USD
BB Middle16.36 USD
BB Lower15.85 USD
BB Width6.16%
ATR (14)0.5423 USD
Vol Ratio (20d)1.90x